JP2018534361A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018534361A5 JP2018534361A5 JP2018539236A JP2018539236A JP2018534361A5 JP 2018534361 A5 JP2018534361 A5 JP 2018534361A5 JP 2018539236 A JP2018539236 A JP 2018539236A JP 2018539236 A JP2018539236 A JP 2018539236A JP 2018534361 A5 JP2018534361 A5 JP 2018534361A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- oligonucleotide
- item
- population
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 68
- 108091034117 Oligonucleotide Proteins 0.000 claims description 60
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 150000003904 phospholipids Chemical class 0.000 claims description 18
- 238000002560 therapeutic procedure Methods 0.000 claims description 12
- 239000002773 nucleotide Substances 0.000 claims description 10
- 125000003729 nucleotide group Chemical group 0.000 claims description 10
- 230000007935 neutral effect Effects 0.000 claims description 8
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 208000035473 Communicable disease Diseases 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 239000002502 liposome Substances 0.000 claims description 6
- 238000011319 anticancer therapy Methods 0.000 claims description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 4
- 239000012678 infectious agent Substances 0.000 claims description 4
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 claims description 2
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 206010017533 Fungal infection Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 108700011259 MicroRNAs Proteins 0.000 claims description 2
- 208000031888 Mycoses Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 208000030852 Parasitic disease Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 108020004459 Small interfering RNA Proteins 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 206010062129 Tongue neoplasm Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 230000000844 anti-bacterial effect Effects 0.000 claims description 2
- 230000000843 anti-fungal effect Effects 0.000 claims description 2
- 230000002141 anti-parasite Effects 0.000 claims description 2
- 230000000840 anti-viral effect Effects 0.000 claims description 2
- 229940121375 antifungal agent Drugs 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 239000003096 antiparasitic agent Substances 0.000 claims description 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 235000012000 cholesterol Nutrition 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 238000000315 cryotherapy Methods 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000003238 esophagus Anatomy 0.000 claims description 2
- 210000003128 head Anatomy 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 238000001794 hormone therapy Methods 0.000 claims description 2
- 206010020718 hyperplasia Diseases 0.000 claims description 2
- 238000002650 immunosuppressive therapy Methods 0.000 claims description 2
- 238000009169 immunotherapy Methods 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 208000026037 malignant tumor of neck Diseases 0.000 claims description 2
- 239000002679 microRNA Substances 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 210000003739 neck Anatomy 0.000 claims description 2
- 239000002777 nucleoside Substances 0.000 claims description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 2
- 231100000590 oncogenic Toxicity 0.000 claims description 2
- 230000002246 oncogenic effect Effects 0.000 claims description 2
- 102000027450 oncoproteins Human genes 0.000 claims description 2
- 108091008819 oncoproteins Proteins 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 239000004055 small Interfering RNA Substances 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 210000001550 testis Anatomy 0.000 claims description 2
- 210000002105 tongue Anatomy 0.000 claims description 2
- 201000006134 tongue cancer Diseases 0.000 claims description 2
- 210000003932 urinary bladder Anatomy 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 238000000034 method Methods 0.000 description 12
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021205957A JP2022027993A (ja) | 2015-10-14 | 2021-12-20 | リポソーム製剤のためのｐ－エトキシ核酸 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562241503P | 2015-10-14 | 2015-10-14 | |
| US62/241,503 | 2015-10-14 | ||
| PCT/US2016/057148 WO2017066643A1 (en) | 2015-10-14 | 2016-10-14 | P-ethoxy nucleic acids for liposomal formulation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021205957A Division JP2022027993A (ja) | 2015-10-14 | 2021-12-20 | リポソーム製剤のためのｐ－エトキシ核酸 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018534361A JP2018534361A (ja) | 2018-11-22 |
| JP2018534361A5 true JP2018534361A5 (OSRAM) | 2019-11-21 |
| JP7441002B2 JP7441002B2 (ja) | 2024-02-29 |
Family
ID=57209904
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018539236A Active JP7441002B2 (ja) | 2015-10-14 | 2016-10-14 | リポソーム製剤のためのｐ－エトキシ核酸 |
| JP2021205957A Withdrawn JP2022027993A (ja) | 2015-10-14 | 2021-12-20 | リポソーム製剤のためのｐ－エトキシ核酸 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021205957A Withdrawn JP2022027993A (ja) | 2015-10-14 | 2021-12-20 | リポソーム製剤のためのｐ－エトキシ核酸 |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US9744187B2 (OSRAM) |
| EP (1) | EP3362563A1 (OSRAM) |
| JP (2) | JP7441002B2 (OSRAM) |
| KR (1) | KR102755601B1 (OSRAM) |
| CN (1) | CN108291227A (OSRAM) |
| AU (1) | AU2016340123B2 (OSRAM) |
| CO (1) | CO2018004821A2 (OSRAM) |
| EA (1) | EA038277B1 (OSRAM) |
| HK (1) | HK1258370A1 (OSRAM) |
| IL (1) | IL258625B2 (OSRAM) |
| MX (1) | MX2018004637A (OSRAM) |
| SG (2) | SG11201802718PA (OSRAM) |
| WO (1) | WO2017066643A1 (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016164916A1 (en) | 2015-04-10 | 2016-10-13 | Thomas Jefferson University | Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory m2 monocytes |
| SG11201802718PA (en) | 2015-10-14 | 2018-05-30 | Bio Path Holdings Inc | P-ethoxy nucleic acids for liposomal formulation |
| CN109963571A (zh) | 2016-09-16 | 2019-07-02 | 拜奥-帕斯控股股份有限公司 | 含有脂质体反义寡核苷酸的组合疗法 |
| KR102925388B1 (ko) | 2017-03-09 | 2026-02-11 | 토마스 제퍼슨 유니버시티 | 안티센스를 사용하여 암을 치료하기 위한 방법 및 조성물 |
| EA201992490A1 (ru) | 2017-04-19 | 2020-03-03 | Байо-Пат Холдингз, Инк. | Р-этокси нуклеиновые кислоты для ингибирования bcl2 |
| AU2018255352B2 (en) * | 2017-04-19 | 2023-11-16 | Bio-Path Holdings, Inc. | P-ethoxy nucleic acids for STAT3 inhibition |
| CA3060090A1 (en) * | 2017-04-19 | 2018-10-25 | Bio-Path Holdings, Inc. | P-ethoxy nucleic acids for igf-1r inhibition |
| CN110650727A (zh) * | 2017-04-19 | 2020-01-03 | 拜奥-帕斯控股股份有限公司 | 用于igf-1r抑制的p-乙氧基核酸 |
| US20210052875A1 (en) | 2018-01-24 | 2021-02-25 | Thomas Jefferson University | Biodiffusion chamber |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1288774C (en) | 1985-01-07 | 1991-09-10 | Deborah A. Eppstein | 1,2-dialkoxy-w-trialkylammonium cationic surfactants |
| US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
| US4870287A (en) | 1988-03-03 | 1989-09-26 | Loma Linda University Medical Center | Multi-station proton beam therapy system |
| US5248671A (en) | 1989-02-15 | 1993-09-28 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of cancer using oligonucleotides |
| US5087617A (en) | 1989-02-15 | 1992-02-11 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of cancer using oligonucleotides |
| US5708154A (en) | 1989-02-24 | 1998-01-13 | City Of Hope | RNA-DNA hybrid molecules of nucleic acid |
| DK0942000T3 (da) | 1989-10-24 | 2004-11-01 | Isis Pharmaceuticals Inc | 2'-modificerede oligonukleotider |
| US5872232A (en) | 1990-01-11 | 1999-02-16 | Isis Pharmaceuticals Inc. | 2'-O-modified oligonucleotides |
| US5859221A (en) | 1990-01-11 | 1999-01-12 | Isis Pharmaceuticals, Inc. | 2'-modified oligonucleotides |
| US5214136A (en) | 1990-02-20 | 1993-05-25 | Gilead Sciences, Inc. | Anthraquinone-derivatives oligonucleotides |
| US5470967A (en) | 1990-04-10 | 1995-11-28 | The Dupont Merck Pharmaceutical Company | Oligonucleotide analogs with sulfamate linkages |
| US5602240A (en) | 1990-07-27 | 1997-02-11 | Ciba Geigy Ag. | Backbone modified oligonucleotide analogs |
| US5610289A (en) | 1990-07-27 | 1997-03-11 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogues |
| US5223618A (en) | 1990-08-13 | 1993-06-29 | Isis Pharmaceuticals, Inc. | 4'-desmethyl nucleoside analog compounds |
| US5623070A (en) | 1990-07-27 | 1997-04-22 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
| DE69126530T2 (de) | 1990-07-27 | 1998-02-05 | Isis Pharmaceutical, Inc., Carlsbad, Calif. | Nuklease resistente, pyrimidin modifizierte oligonukleotide, die die gen-expression detektieren und modulieren |
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| US6111094A (en) * | 1990-08-14 | 2000-08-29 | Isis Pharmaceuticals Inc. | Enhanced antisense modulation of ICAM-1 |
| US5672697A (en) | 1991-02-08 | 1997-09-30 | Gilead Sciences, Inc. | Nucleoside 5'-methylene phosphonates |
| US5766855A (en) | 1991-05-24 | 1998-06-16 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity and sequence specificity |
| US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
| DK51092D0 (da) | 1991-05-24 | 1992-04-15 | Ole Buchardt | Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf |
| US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
| US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
| US5525719A (en) * | 1991-08-30 | 1996-06-11 | Chemgenes Corporation | N-protected-2'-O-methyl-and N-protected-3'-O-methyl-ribonucleosides and their phosphoramidite derivatives |
| US5700922A (en) | 1991-12-24 | 1997-12-23 | Isis Pharmaceuticals, Inc. | PNA-DNA-PNA chimeric macromolecules |
| ATE244259T1 (de) | 1992-02-12 | 2003-07-15 | Chromagen Inc | Verwendungen von fluoreszierenden n-nukleosiden und dessen analogen |
| US5652099A (en) | 1992-02-12 | 1997-07-29 | Conrad; Michael J. | Probes comprising fluorescent nucleosides and uses thereof |
| GB9211979D0 (en) | 1992-06-05 | 1992-07-15 | Buchard Ole | Uses of nucleic acid analogues |
| US5438131A (en) | 1992-09-16 | 1995-08-01 | Bergstrom; Donald E. | 3-nitropyrrole nucleoside |
| US5801029A (en) | 1993-02-16 | 1998-09-01 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| US5858988A (en) | 1993-02-24 | 1999-01-12 | Wang; Jui H. | Poly-substituted-phenyl-oligoribo nucleotides having enhanced stability and membrane permeability and methods of use |
| US5801005A (en) | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
| US6015886A (en) * | 1993-05-24 | 2000-01-18 | Chemgenes Corporation | Oligonucleotide phosphate esters |
| EP0678017B1 (en) | 1993-11-05 | 1998-04-01 | Amgen Inc. | Liposome preparation and material encapsulation method |
| US5446137B1 (en) | 1993-12-09 | 1998-10-06 | Behringwerke Ag | Oligonucleotides containing 4'-substituted nucleotides |
| US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
| GB9506466D0 (en) | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
| US5855911A (en) * | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
| US5670663A (en) | 1996-02-14 | 1997-09-23 | Regents Of The University Of California | Recovery of taxanes from conifers |
| US5760395A (en) | 1996-04-18 | 1998-06-02 | Universities Research Assoc., Inc. | Method and apparatus for laser-controlled proton beam radiology |
| US5739169A (en) | 1996-05-31 | 1998-04-14 | Procept, Incorporated | Aromatic compounds for inhibiting immune response |
| US7309692B1 (en) | 1996-07-08 | 2007-12-18 | Board Of Regents, The University Of Texas System | Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1 |
| US5886165A (en) | 1996-09-24 | 1999-03-23 | Hybridon, Inc. | Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonucleotides segments |
| US5849902A (en) | 1996-09-26 | 1998-12-15 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
| US6977244B2 (en) | 1996-10-04 | 2005-12-20 | Board Of Regents, The University Of Texas Systems | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
| US5908845A (en) | 1996-10-30 | 1999-06-01 | Segev; David | Polyether nucleic acids |
| US7262173B2 (en) * | 1997-03-21 | 2007-08-28 | Georgetown University | Chemosensitizing with liposomes containing oligonucleotides |
| US7704962B1 (en) | 1997-10-03 | 2010-04-27 | Board Of Regents, The University Of Texas System | Small oligonucleotides with anti-tumor activity |
| US7285288B1 (en) | 1997-10-03 | 2007-10-23 | Board Of Regents, The University Of Texas System | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
| US6274725B1 (en) * | 1998-06-02 | 2001-08-14 | Isis Pharmaceuticals, Inc. | Activators for oligonucleotide synthesis |
| AU2197600A (en) | 1998-12-30 | 2000-07-24 | Oligos Etc. Inc. | Acid stable backbone modified end-blocked nucleic acids and therapeutic uses thereof |
| US20030180789A1 (en) | 1998-12-30 | 2003-09-25 | Dale Roderic M.K. | Arrays with modified oligonucleotide and polynucleotide compositions |
| US7098192B2 (en) | 1999-04-08 | 2006-08-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of STAT3 expression |
| AU7868400A (en) | 1999-10-08 | 2001-04-23 | Alza Corporation | Neutral-cationic lipid for nucleic acid and drug delivery |
| US20050186264A1 (en) * | 2000-10-12 | 2005-08-25 | Kiani Mohammad F. | Targeting drug/gene carriers to irradiated tissue |
| US7060690B2 (en) * | 2001-01-22 | 2006-06-13 | Genta Incorporated | Methods and compositions for treating a cell-proliferative disorder using CRE decoy oligomers, BCL-2 antisense oligomers, and hybrid oligomers thereof |
| US7425545B2 (en) * | 2001-07-25 | 2008-09-16 | Isis Pharmaceuticals, Inc. | Modulation of C-reactive protein expression |
| EP1465995B1 (en) * | 2002-01-17 | 2008-07-30 | The University of British Columbia | Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same |
| US20030147813A1 (en) | 2002-02-07 | 2003-08-07 | John Lyons | Method for treating chronic myelogenous leukemia |
| US9150605B2 (en) | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
| JP2006507841A (ja) | 2002-11-14 | 2006-03-09 | ダーマコン， インコーポレイテッド | 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ |
| US7871769B2 (en) | 2004-04-09 | 2011-01-18 | Genomic Health, Inc. | Gene expression markers for predicting response to chemotherapy |
| WO2007027775A2 (en) * | 2005-08-29 | 2007-03-08 | Isis Pharmaceuticals, Inc. | Methods for use in modulating mir-122a |
| US20070190382A1 (en) | 2006-02-10 | 2007-08-16 | Fischer Bernhard A | Hydrocarbon reformer system |
| US7915399B2 (en) | 2006-06-09 | 2011-03-29 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
| US20080171718A1 (en) * | 2006-11-08 | 2008-07-17 | Brown Bob D | Methods and Compositions for Treating Cancer Using BCL-2 Antisense Oligomers, Tyrosine Kinase Inhibitors, and Chemotherapeutic Agents |
| PL2167124T3 (pl) | 2007-06-29 | 2012-12-31 | Statens Seruminstitut | Zastosowanie monomikoliloglicerolu (MMG) jako adiuwantu |
| JP5753382B2 (ja) | 2007-11-06 | 2015-07-22 | アディウティーダ ファーマシューティカルズ ゲーエムベーハー | 修飾されたオリゴリン酸基を含有する免疫賦活オリゴリボヌクレオチドアナログ |
| CN102239178B (zh) | 2008-10-02 | 2017-06-23 | Vib研究所 | 抑制PlGF以治疗费城染色体阳性白血病 |
| US9289505B2 (en) | 2010-08-17 | 2016-03-22 | Rutgers, The State University Of New Jersey | Compositions and methods for delivering nucleic acid molecules and treating cancer |
| WO2012112730A2 (en) | 2011-02-15 | 2012-08-23 | Merrimack Pharmaceuticals, Inc. | Compositions and methods for delivering nucleic acid to a cell |
| US9322015B2 (en) * | 2011-03-09 | 2016-04-26 | The Brigham And Women's Hospital, Inc. | Methods of using microRNA-26a to promote angiogenesis |
| RS58489B1 (sr) | 2011-04-01 | 2019-04-30 | Ionis Pharmaceuticals Inc | Modulacija eksprimiranja transduktora signala i aktivatora transkripcije 3 (stat3) |
| JP2016524621A (ja) * | 2013-06-03 | 2016-08-18 | バル−イラン ユニバーシティ | ウィスコットアルドリッチ症候群タンパク質を変調するリポソーム |
| JP6527516B2 (ja) * | 2013-12-03 | 2019-06-05 | ノースウェスタン ユニバーシティ | リポソーム粒子、前述のものを作製する方法及びその使用 |
| WO2016164916A1 (en) | 2015-04-10 | 2016-10-13 | Thomas Jefferson University | Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory m2 monocytes |
| SG11201802718PA (en) | 2015-10-14 | 2018-05-30 | Bio Path Holdings Inc | P-ethoxy nucleic acids for liposomal formulation |
| CN109963571A (zh) | 2016-09-16 | 2019-07-02 | 拜奥-帕斯控股股份有限公司 | 含有脂质体反义寡核苷酸的组合疗法 |
| KR102925388B1 (ko) | 2017-03-09 | 2026-02-11 | 토마스 제퍼슨 유니버시티 | 안티센스를 사용하여 암을 치료하기 위한 방법 및 조성물 |
| CN110650727A (zh) | 2017-04-19 | 2020-01-03 | 拜奥-帕斯控股股份有限公司 | 用于igf-1r抑制的p-乙氧基核酸 |
| EA201992490A1 (ru) | 2017-04-19 | 2020-03-03 | Байо-Пат Холдингз, Инк. | Р-этокси нуклеиновые кислоты для ингибирования bcl2 |
| CA3060090A1 (en) | 2017-04-19 | 2018-10-25 | Bio-Path Holdings, Inc. | P-ethoxy nucleic acids for igf-1r inhibition |
| AU2018255352B2 (en) | 2017-04-19 | 2023-11-16 | Bio-Path Holdings, Inc. | P-ethoxy nucleic acids for STAT3 inhibition |
| MX2021011760A (es) | 2019-03-28 | 2021-12-10 | Univ Jefferson | Metodos para el tratamiento de canceres usando antisentido. |
| CN112830354A (zh) | 2019-11-22 | 2021-05-25 | 富泰华工业（深圳）有限公司 | 基于区块链系统的电梯调度系统、装置、方法及存储介质 |
-
2016
- 2016-10-14 SG SG11201802718PA patent/SG11201802718PA/en unknown
- 2016-10-14 WO PCT/US2016/057148 patent/WO2017066643A1/en not_active Ceased
- 2016-10-14 KR KR1020187013428A patent/KR102755601B1/ko active Active
- 2016-10-14 AU AU2016340123A patent/AU2016340123B2/en not_active Ceased
- 2016-10-14 EP EP16788346.1A patent/EP3362563A1/en active Pending
- 2016-10-14 HK HK19100741.1A patent/HK1258370A1/zh unknown
- 2016-10-14 EA EA201890940A patent/EA038277B1/ru unknown
- 2016-10-14 IL IL258625A patent/IL258625B2/en unknown
- 2016-10-14 US US15/294,223 patent/US9744187B2/en active Active
- 2016-10-14 SG SG10202104058XA patent/SG10202104058XA/en unknown
- 2016-10-14 JP JP2018539236A patent/JP7441002B2/ja active Active
- 2016-10-14 MX MX2018004637A patent/MX2018004637A/es unknown
- 2016-10-14 CN CN201680068357.0A patent/CN108291227A/zh active Pending
-
2017
- 2017-07-21 US US15/657,083 patent/US10335428B2/en active Active
-
2018
- 2018-05-07 CO CONC2018/0004821A patent/CO2018004821A2/es unknown
-
2019
- 2019-05-30 US US16/426,798 patent/US10898506B2/en active Active
-
2020
- 2020-12-18 US US17/127,664 patent/US12097214B2/en active Active
-
2021
- 2021-12-20 JP JP2021205957A patent/JP2022027993A/ja not_active Withdrawn
-
2024
- 2024-09-19 US US18/890,384 patent/US20250255897A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102623786B1 (ko) | 근위축증 및 근긴장성 이영양증을 치료하는 조성물 및 방법 | |
| CN108026533B (zh) | 拮抗性pdl1适体及其在癌症治疗中的应用 | |
| ES2746340T3 (es) | Composición que contiene ARN para el tratamiento de enfermedades tumorales | |
| AU2013306006B2 (en) | Polynucleotides having bioreversible groups | |
| Rengaswamy et al. | RGD liposome-protamine-siRNA (LPR) nanoparticles targeting PAX3-FOXO1 for alveolar rhabdomyosarcoma therapy | |
| JP2019513371A (ja) | 核酸ポリペプチド組成物とその使用 | |
| TWI703214B (zh) | 具拮抗ｐｄ-１功能的適體分子於癌症治療相關之應用 | |
| CN110643609B (zh) | 一种核苷类似物药物分子构建的药物适配体及其制备方法和应用 | |
| IL317818A (en) | Oligonucleotides to reduce PD-L1 expression | |
| JP2020517632A5 (OSRAM) | ||
| JP2017518043A5 (OSRAM) | ||
| IL269608B1 (en) | Compounds Containing Phosphorus-Ethoxy-Based Nucleic Acids for STAT3 Inhibition for Use in the Treatment of Cancer and Autoimmune Diseases | |
| US20240158794A1 (en) | NUCLEOSIDE CONTAINING siRNAS FOR TREATING VIRAL DISEASES | |
| JP2020114835A (ja) | 療法用ナノ粒子および関連する組成物、方法、およびシステム | |
| US20210269797A1 (en) | Methods and compositions for targeting pd-l1 | |
| JP2023532032A (ja) | 血液脳関門浸透アプタマー及びその利用 | |
| JP2020517646A5 (OSRAM) | ||
| WO2021007465A2 (en) | Cancer treatment using targeted sirna pharmaceutical formulations to downregulate expression of prdm14 protein | |
| JP6536964B2 (ja) | 免疫賦活活性を有する核酸多糖複合体の抗腫瘍薬としての応用 | |
| CN105779458B (zh) | 对非小细胞肺癌具有抑制作用的核糖核酸适配体及包含其的药物组合物 | |
| TWI604846B (zh) | 拮抗性ｃｔｌａ－４適體及其於增進免疫活性之應用 | |
| CA3224708A1 (en) | Targeting oncogenic kras with molecular brush-conjugated antisense oligonucleotide | |
| KR20230164124A (ko) | 구형 핵산 백신 구조를 사용한 다중 t 세포 유형 표적화 | |
| WO2016068160A1 (ja) | 局所投与用リポプレックスの新規製造方法及び該リポプレックスを使用する抗腫瘍剤 | |
| JP2019163302A (ja) | 免疫賦活活性を有する核酸多糖複合体の抗腫瘍薬としての応用 |